Navigation Links
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
Date:9/17/2008

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending dose studies conducted at several leading clinical sites in the United States. The trials are expected to enroll up to 60 patients and are designed to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518.

SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild-type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an effective treatment for other hematological malignancies with mutations and re-arrangements in the JAK2 gene.

"The entry of SB1518 into the clinical phase marks an important milestone for S*BIO and potentially offers a new targeted therapy for this group of difficult-to-treat patients that represent a significant unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518 has demonstrated exciting anti-proliferative and anti-tumor activity, combined with excellent tolerability in relevant in vitro and in vivo models. We are pleased to conduct our company's first clinical trials in the United States at well respected centers such as The University of Texas M.D. Anderson Cancer Center, the University of Chicago Medical Center and the Fred Hutchinson Cancer Research Center."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is currently in Phase I trials in Singapore and Canada. S*BIO's target-driven approach to developing innovative small molecule therapies for cancer is built on a profound understanding of cancer biology, which the company aggressively translates into "best-in-class" and "first-in-class" drugs. The company has a strong team of experienced drug discovery and development scientists, and state-of-the-art infrastructure which includes a comprehensive technology platform covering the drug discovery value chain, from target identification and validation through lead optimisation to pre-clinical and clinical development.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its second compound, SB1518, commenced Phase I clinical trials in 2008 and has received orphan drug designation from the U.S. FDA. A third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Corporate Development

Tel: +65 6827 5000 (Singapore)

Stephen_rhind@sbio.com

Russo Partners:

Tony Russo +1 212-845-4251

Tony.Russo@russopartnersllc.com

Andreas Marathovouniotis +1 212-845-4253

Andreas.Marathis@russopartnersllc.com


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
4. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
5. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
6. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
7. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
8. Isis Initiates Clinical Trial of CRP Drug
9. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
10. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
(Date:9/5/2017)...  Xyntek Inc. has announced another milestone in their continued growth and success ... the growing demands of customer engagements regionally.  ... new Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, ... Xyntek's recently opened ... ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... PITTSBURGH...An inventor, from Richmond Hill, ... charts in hospitals and medical facilities, so he invented the COMPLETE PATIENT CHART. , ... charts. In doing so, it offers an improved alternative to paper charts and clipboards. ...
(Date:9/25/2017)... Pa. (PRWEB) , ... September ... ... provider of specialized science and technology-enabled services supporting clinical research, today announces ... topics addressing key aspects of the drug development lifecycle at upcoming industry ...
(Date:9/25/2017)... , ... September 25, 2017 , ... Earlypicker is expanding ... a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the nation. ... company that’s already well-known for the great offerings that allow Koreans everywhere to look ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a poignant book that ... Unicorn” is the creation of published author, Dayna Chantel, an artist and a writer. ... wide to march aboard the cypress ark-vessel. Male and female, no matter what species, ...
(Date:9/25/2017)... , ... September 25, 2017 , ... Emerald Ash Borers kill Ash trees ... be seen throughout the Philadelphia region. A video by Rob Nagy, ISA Certified Arborist ... Ash trees. While several are dead or showing signs of decline from Emerald Ash ...
Breaking Medicine News(10 mins):